USA flag logo/image

An Official Website of the United States Government

SBIR Phase I:Commercial Scale-up of Algal Fermentation Processes to Manufacture…

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
99022
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
1013471
Solicitation Year:
N/A
Solicitation Topic Code:
BT2
Solicitation Number:
N/A
Small Business Information
Algisys
6610 Hidden Woods Trail Cleveland, OH 44143-3578
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: SBIR Phase I:Commercial Scale-up of Algal Fermentation Processes to Manufacture Eicosapentaenoic Acid
Agency: NSF
Contract: 1013471
Award Amount: $150,000.00
 

Abstract:

This Small Business Innovation Research (SBIR) Phase I project is focused on completing the research necessary to begin commercializing the production of eicosapentaenoic acid (EPA) from algae. Algisys, LLC has partnered with Virginia Tech to further develop patent-pending technology for the production of EPA via algal fermentation, using inexpensive biodiesel-derived crude glycerol as a feedstock. This SBIR project is expected to result in the technical data necessary to initiate scale-up work on a process to convert waste glycerol into a high value nutritional oil containing EPA. Algisys plans to be the first company in the world to commercially produce EPA directly from algae. The broader/commercial impacts of this research involve the creation of a completely new source of EPA, which is currently derived solely from the oil of select types of marine fish. Fish oil contains low levels of omega-3 fatty acids, such as EPA, due to the consumption of algae by fish as part of the marine food chain. Omega-3s represent a multi-billion dollar market and are essential in the human diet for proper growth, development, and good health. Over 8,000 scientific studies and 40 years of research have shown that omega-3s have significant health benefits, and can be used to prevent/treat a variety of disorders: cardiovascular diseases, arthritis/inflammatory diseases, immune system disorders, Alzheimer?s, and macular degeneration. Algisys intends to help meet the rapidly growing demand for EPA using patent-pending technology that merits further development, and is believed to be both scalable and cost effective.

Principal Investigator:

Charles L. Roe
PhD
4406840980
charles@algisys.com

Business Contact:

Charles L. Roe
PhD
4406840980
charles@algisys.com
Small Business Information at Submission:

Algisys
6610 Hidden Woods Trail Cleveland, OH 44143

EIN/Tax ID: 270660989
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No